Physician profile
David A King
NPI 1467416636
$2,183.26
in general payments reported to CMS, 2019-2025
11 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $410 · 2023: $593 · 2024: $554 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,562.60 | 2021-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $222.40 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $128.67 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2022-2024 | Eliquis, Camzyos |
| Amgen INC. | $28.44 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $25.56 | 2022-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.18 | 2024-2025 | Lifevest |
| Boston Scientific Corporation | $19.96 | 2025 | Watchman Flx |
| Medtronic, INC. | $18.95 | 2023 | Corevalve Evolut R |
| Pfizer INC. | $16.03 | 2023 | |
| Smith+Nephew, INC. | $14.65 | 2025 | Pico 7 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.